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ABSTRACT 
A series of novel heteroaryl thiazoles (3a-u) was synthesized by the Hantzsch reaction of 
various α-bromoketones (1a-c) with the heteroaryl thiourea (2a-g) using InCl3 as a catalyst in a 
shorter reaction time. All the novel thiazole derivatives were characterized and screened for their 
in vitro cytotoxic activity against DAL and EAC cells. Among the 21 compounds screened, the 
compounds 3b, 3d, 3f, 3h, 3j, 3k, 3m, 3p, 3r, 3t and 3u were found to be the most active against DAL 
cells with IC50 values less than 41.60 μg/mL and the compounds 3d, 3q, 3r and 3t were found to be 
the most active against EAC cells with IC50 values less than 41.60 μg/mL. 
Keywords:   Thiazole, Isoxazole, Benzothiophene, Benzodioxepine, Indium chloride, Cytotoxicity. 
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1. INTRODUCTION  
Benzothiophene moiety is a prevalent 
scaffold in a number of naturally occurring and 
synthetic molecules with attractive biological 
activities [1]. Davis et al. identified a new 
benzothiophene containing Rho kinase inhibitor 
scaffold in an ultra high throughput enzyme 
activity screen [2]. Benzothiophene derivative 
strongly inhibited the oxidation of arachidonic 
acid by recombinant human 5-lipoxygenase and 
the production of LTB4 in calcium ionophore-
stimulated HWB [3]. Benzothiophene piperidine 
urea inhibited FAAH by covalently modifying the 
enzyme’s active site serine nucleophile [4]. 
Benzothiophenyl piperazinyl piperidine derivative 
showed reduction of hepatic de nova fatty acid 
synthesis in rats after oral administration [5].  
Benzodioxepin derivative possessed 
cytotoxic activity against human breast cancer 
cells with IC50 = 5.04 ± 1.68 µm nearly equipotent 
as 5-Flurouracil [6]. Benzodioxepin derivatives 
were identified as novel survival motor neuron 
(SMN) protein modulators [7]. 1,5-Benzodioxepin 
derivatives displayed high affinity for muscarinic 
M1-M3 receptors [8]. 
Heterocycles containing an isoxazole ring 
system are found to exhibit a wide spectrum of 
biological activities [9]. Isoxazoles displayed high in 
vitro neuroprotective activity against oxidative 
stress-induced death of neuronal HT22 cells [10]. 
Isoxazolyl dihydropyridines exhibited inhibition 
of the multidrug-resistance transporter (MDR-1) 
[11]. Isoxazole derivatives have shown very potent 
analgesic activity when compared with standard 
drug Pentazocine [12]. Isoxazolyl pyrazoles 
exhibited the maximum antinociceptive activity 
[13]. 
Thiazole derivatives are known to exhibit 
various pharmacological properties [14]. Many 
commercially available drugs (figure 1) including, 
Riluzole (anticonvulsant), Sulfathiazole 
(antibacterial) and Zolamine (antihistamine) are 
derived from thiazole entities. Thiazole 
derivatives displayed significant anti-
inflammatory and antibacterial activities when 
compared to well known reference drugs 
Indomethacin and Cefixime respectively [15]. 
Thiazole derivatives emerged as the most active 
antifungal compounds against Aspergillus flavus 
and Aspergillus fumigatus [16]. Thiazole chalcones 
exhibited potential antitumor activity in vitro 
against S180 xenograft in mice [17]. Thiazole 
derivatives were identified as potent pan 
inhibitors of Akt kinases [18]. 
Since the past few decades, the literature 
has been enriched with progressive finding about 
the cytotoxic activities of various substituted 
thiazoles derivatives. Keeping in the view of these 
observations and in continuation of our research 
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work on the synthesis of biheterocyclic 
compounds [19-23], we herein report the synthesis 
of some novel benzodioxepinthiazoles, 
isoxazolylthiazoles and benzothiophenylthiazoles 
which have been found to possess an interesting 
profile of cytotoxic activities.    
2. CHEMISTRY 
Synthesis of the thiazole (Scheme 1) was 
accomplished following the well known 
Hantzsch’s thiazole synthesis involving the 
reaction of synthons (1a-c) and (2a-g). Various 
commercial aryl thiourea (2a-g) and commercially 
available α-bromoketones (1a-c) were cyclised in 
the presence of 10 mol% InCl3 as a Lewis acid 
catalyst in refluxing ethanol at 70 °C for 2 hours to 
afford the desired thiazole derivatives (3a-u) in 
high yield (84-94%). It was hypothesized that a 
critical choice of metal chloride might efficiently 
catalyze the Hantzsch’s thiazole synthesis by 
forming a better activated intermediate (Figure 2).  
The role of the InCl3 can be postulated in 
terms of Lewis acidity of the InCl3 leading to its 
interaction with the carbonyl oxygen of ketone (I) 
and (III) resulting in its increased polarization 
leading to increased electrophilicity of the 
carbocation and thus, promoting condensation 
step A and cyclisation step B to produce five 
membered ring (IV), which on dehydration 
afforded (V). In the absence of InCl3, the product 
was obtained in a moderate yield (50-60%) after 
long reaction times (4-6 h).  
Though several catalysts such as Ionic 
liquid [24], acetic acid [25], β-cyclodextrine [26] and 
ammonium-12-molybdophosphate (AMP) [27] have 
been employed for Hantzsch’s thiazole synthesis, 
some of these procedures are complicated by 
harsh reaction conditions, use of harmful organic 
solvents, low yield and difficulties in the work up 
procedures. To the best of our knowledge, InCl3 
has not been used as a catalyst for Hantzsch’s 
thiazole synthesis and it is now found to be 
effective than other catalysts investigated.   
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Figure - 1: Some biologically active thiazoles 
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Scheme -1:  Synthesis of the compounds (3a-u) 
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Figure - 2: Plausible mechanism for the synthesis of (3a-u) 
3. EXPERIMENTAL 
The melting points were determined by open 
capillary method using electric melting point 
apparatus and are uncorrected. The IR spectra 
(KBr disc) were recorded on a Shimadzu-8400S 
FT-IR Spectrophotometer. 1H NMR spectra were 
recorded on Bruker 300 MHz (for compounds 3d-
u) and 400 MHz (for compounds 3a-c) 
spectrometer. 13C NMR was recorded on Bruker 
400 MHz spectrometer. DMSO-d6 and CDCl3 were 
used as a solvents and TMS as an internal 
standard. The chemical shifts were expressed in δ 
ppm. The mass spectra were recorded on an 
Agilent-Single Quartz ESI-MS. The purity of the 
compounds was checked by TLC. The elemental 
analyses were carried out using Elemental Vario 
Micro Cube CHN Rapid Analyzer. All the 
compounds gave satisfactory elemental analysis.  
3.1. General procedure for the synthesis of 
thiazole derivatives (3a-u).  
To a stirring solution of α-bromoketones 
(1.56 mmol) (1a-c) and phenylthiourea 
derivatives (1.56 mmol) (2a-g) in ethanol (15 mL) 
was added InCl3 (10 mol %). The reaction flask 
was heated at 70 °C in an oil bath for 1.5-2 h. The 
completion of the reaction was monitored by TLC. 
After completion of the reaction, the reaction 
mixture was concentrated to one fourth volume 
and poured on to crushed ice. The solid separated 
was filtered and washed with cold water. The 
crude product was dried and recrystallised from 
ethanol. 
4. RESULT AND DISCUSSION 
The structures of novel thiazole 
derivatives (3a-u) were established from IR, 
1HNMR, 13C NMR and ESI-MS data as illustrated 
for a representative example. In the IR spectrum 
of 5-(2-benzoylamino-thiazol-4-yl)-isoxazole-3-
carboxylic acid ethyl ester (3g), the amide 
carbonyl stretching frequency was observed at 
1683 cm-1 where as the ester carbonyl stretching 
frequency appeared at 1733 cm-1. The N-H 
stretching frequency showed a strong band at 
3230 cm-1. The 1HNMR spectrum of the compound 
(3g) exhibited a triplet in the region at δ 1.32 (J = 
7.2 Hz) due to methyl protons of ethyl group. A 
quartet was appeared at δ 4.39 (J = 7.2 Hz) due to 
methylene protons of ethyl group. A singlet was 
observed at δ 7.19 due to the presence of aromatic 
proton. A triplet appeared in the region δ 7.54-
7.59 is due to two aromatic protons. A doublet 
appeared at δ 7.64 (J = 7.2 Hz) is due to one 
aromatic proton.  A doublet appeared at δ 8.12 (J = 
8.4 Hz) is due to three aromatic protons. The N-H 
proton was resonated as a singlet at δ 10.56 which 
was further confirmed by D2O exchange 
experiment. The 13C NMR spectrum of the 
compound (3g) is given in the experimental 
section. The mass spectrum (ESI) of 5-(2-p-
tolylamino-thiazol-4-yl)-isoxazole-3-carboxylic 
acid ethyl ester (3e) displayed a [M+1] peak at 
330.    
4.1. Biological activity 
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The cytotoxic activity of newly 
synthesized compounds was examined in vitro on 
Dalton’s Ascitic Lymphoma (DAL) and Ehrlich 
Ascites Carcinoma (EAC) cells using Trypan blue 
dye exclusion assay [28].  
Ascitic fluid withdrawn from the 
peritoneum of DAL and EAC inoculated mouse 
was washed with ice cold phosphate buffer saline 
(PBS) of pH 7.4. Stock cell suspension was 
adjusted to 1×106 cell/0.2 mL by PBS using 
hemocytometer. The cells were incubated with 
desired test drug concentration in a final volume 
of 1 mL for 3 hr at 37 °C in a CO2 incubator with 
continuous flow of 5% CO2. 5-Flurorouracil was 
used as positive control. After incubation, 0.2 mL 
of cell line was taken and made upto of final 
concentration with PBS (0.3 mL), trypan blue (0.5 
mL), mixed well and kept aside for 5 min. The 
total number of dead and living cells counted 
using a hemocytometer and the percentage 
viability or cytotoxicity was calculated. All the 
procedures were done in triplicate manner. 
4.1.1. In Vitro Cytotoxic Screening 
The newly synthesized compounds were 
evaluated for their in vitro cytotoxic activity 
against Dalton’s Ascites Lymphoma (DAL) and 
Ehrlich Ascites Carcinoma (EAC) cells. 5-
Fluorouracil which is one of the most effective 
anticancer agents was used as the reference drug 
in this study. The relationship between surviving 
fraction and drug concentration was plotted to 
obtain the survival curve of Dalton’s Ascites 
Lymphoma (DAL) and Ehrlich Ascites Carcinoma 
(EAC) cells. The response parameter calculated 
was the IC50 value, which corresponds to the 
concentration required for 50% inhibition of cell 
viability. The IC50 of the synthesized compounds 
compared to the reference drug are shown in 
(Table 1) and the results are represented 
graphically in (Figure 3).    
 
Table -1: Results of in vitro cytotoxic activity of the synthesized compounds on DAL and EAC  cells 
in IC50 (μg/mL) 
 
Compounds 
 
R1                           
 
R 
Cancer cell inhibition 
DAL EAC 
3a (4-F) Phenyl  56.86 127.9 
3b (4-Cl) Phenyl 28.08 86.78 
3c (3-CF3) Phenyl 51.45 68.06 
3d 2-Pyridyl 17.72 28.73 
3e p-Tolyl 105.70 54.70 
3f (2,3-Dimethoxy) Phenyl 26.62 107.60 
3g Benzoyl 102.00 54.25 
3h (4-F) Phenyl  40.07 155.70 
3i (4-Cl) Phenyl 60.04 46.62 
3j (3-CF3) Phenyl 39.84 102.0 
3k 2-Pyridyl 29.87 56.69 
3l p-Tolyl 43.55 85.59 
3m (2,3-Dimethoxy) Phenyl 40.84 64.24 
3n Benzoyl 59.83 59.60 
3o (4-F) Phenyl  56.61 43.70 
3p (4-Cl) Phenyl 38.56 59.68 
3q (3-CF3) Phenyl 73.84 39.88 
3r 2-Pyridyl 26.84 30.03 
3s p-Tolyl 50.71 59.72 
3t (2,3-Dimethoxy) Phenyl 28.65 40.87 
3u Benzoyl 15.76 50.69 
                                          5-Fluorouracil 41.60 41.60 
O
N
O
O
O
O
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The investigation of in vitro cell 
cytotoxicity revealed that the most of the tested 
compounds exhibited good activity against DAL 
cells.  The compounds 3b [R = Isoxazole, R1 = (4-
Cl) phenyl], 3d (R = Isoxazole, R1 = 2-Pyridyl), 3f 
[R = Isoxazole, R1 = (2,3-Dimethoxy) Phenyl], 3h 
[R = Benzodioxepine, R1 = (4-F) Phenyl], 3j [R = 
Benzodioxepine, R1 = (3-CF3) Phenyl], 3k [R = 
Benzodioxepine, R1 = 2-Pyridyl], 3m [R = 
Benzodioxepine, R1 = (2,3-Dimethoxy) Phenyl], 3p 
[R = Benzothiophene, R1 = (4-Cl) Phenyl], 3r [R = 
Benzothiophene, R1 = 2-Pyridyl], 3t [R = 
Benzothiophene, R1 = (2,3-Dimethoxy) Phenyl] 
and 3u [R = Benzothiophene, R1 = Benzoyl] 
displayed excellent activity against DAL cell with 
IC50 value of < 41.60 μg/mL.  These derivatives are 
more potent than 5-Fluorouracil (positive control).  
The compounds 3a [R = Isoxazole, R1 = (4-Cl) 
Phenyl], 3c [R = Isoxazole, R1 = (3-CF3) Phenyl], 3i 
[R = Benzodioxepine, R1 = (4-Cl) Phenyl], 3l [R = 
Benzodioxepine, R1 = p-Tolyl], 3n [R = 
Benzodioxepine, R1 = Benzoyl], 3o [R = 
Benzothiophene, R1 = (4-F) Phenyl] and 3s [R = 
Benzothiophene, R1 = p-Tolyl] exhibited moderate 
activity with IC50 values between 43 - 61 μg/mL. 
The rest of the compounds showed poor activity. 
The investigation of in vitro cell 
cytotoxicity revealed that a few of the tested 
compounds exhibited good activity against EAC 
cells. The compounds 3d [R = Isoxazole, R1 = 2-
Pyridyl], 3q [R = Benzothiophene, R1 = (3-CF3) 
Phenyl), 3r [R = Benzothiophene, R1 = 2-Pyridyl] 
and 3t [R = Benzothiophene, R1= (2,3-Dimethoxy) 
Phenyl] displayed excellent activity against EAC 
cell with IC50 value of < 41.60 μg/mL. These 
derivatives are more potent than 5-Fluorouracil.  
Figure - 3: Graphical representation of in vitro 
cytotoxic activity of the synthesized 
compounds on DAL and EAC cells in IC50 
(μg/mL) 
The compounds 3e [R = Isoxazole, R1 = p-
Tolyl], 3g [R = Isoxazole, R1 = Benzoyl], 3i [R = 
Benzodioxepine, R1 = (4-Cl) Phenyl], 3k [R = 
Benzodioxepine, R1 = 2-Pyridyl], 3n [R = 
Benzodioxepine, R1 = Benzoyl], 3o [R = 
Benzothiophene, R1 = (4-F) Phenyl], 3p [R = 
Benzothiophene, R1 = (4-Cl) Phenyl], 3s [R = 
Benzothiophene, R1 = p-Tolyl] and 3u [R = 
Benzothiophene, R1 = Benzoyl] exhibited 
moderate activity with IC50 values between 46 - 60 
μg/mL. The rest of the compounds showed poor 
activity. 
4.2. Characterization  
4.2.1. 5-[2-(4-Fluoro-phenylamino)-thiazol-
4-yl]-isoxazole-3-carboxylic acid methyl ester 
(3a) 
Yield 91%; colorless solid; m.p. 146-148 
°C; IR (KBr, cm-1): 1723 (ester C=O), 3220 (N-H); 
1H NMR (400 MHz, DMSO-d6): δ = 1.41 (t, 3H, J = 
5.4 Hz, CH3 of ethyl), 4.46 (q, 2H, J = 5.4 Hz, CH2 of 
ethyl), 6.94 (s, 1H, Ar-H), 7.07-7.42 (m, 5H, Ar-H) 
ppm; Anal. Calcd for C15H12FN3O3S: C, 54.05: H, 
3.63: N, 12.61. Found: C, 53.85: H, 3.56: N, 12.50.  
4.2.2. 5-[2-(4-Chloro-phenylamino)-thiazol-
4-yl]-isoxazole-3-carboxylic acid ethyl ester 
(3b) 
Yield 84%; colorless solid; m.p. 174-176 
°C; IR (KBr, cm-1): 1728 (ester C=O), 3226 (N-H); 
1H NMR (400 MHz, CDCl3): δ = 1.42 (t, 3H, J = 5.4 
Hz, CH3 of ethyl), 4.44 (q, 2H, J = 7.2 Hz, CH2 of 
ethyl), 6.96-7.41 (m, 7H, Ar-H) ppm; Anal. Calcd 
for C15H12ClN3O3S: C, 51.51: H, 3.46: N, 12.01. 
Found: C, 51.38: H, 3.39: N, 11.91.  
4.2.3. 5-[2-(3-Trifluoromethyl-
phenylamino)-thiazol-4-yl]-isoxazole-3-
carboxylic acid ethyl ester (3c)  
Yield 87%; colorless solid; m.p. 138-141 
°C; IR (KBr, cm-1): 1732 (ester C=O),  3243 (N-H); 
1H NMR (400 MHz, CDCl3): δ = 1.42 (t, 3H, J = 5.4 
Hz, CH3 of ethyl), 4.45 (q, 2H, J = 5.1 Hz, CH2 of 
ethyl), 7.07 (s, 1H, Ar-H), 7.28 (s, 1H, Ar-H), 7.42 
(d, 1H, Ar-H, J = 5.7 Hz), 7.53 (t, 1H, J = 6.0 Hz, Ar-
H), 7.66-7.74 (m, 2H, Ar-H) ppm; Anal. Calcd for 
C16H12F3N3O3S: C, 50.13: H, 3.16: N, 10.96. Found: 
C, 50.01: H, 3.02: N, 10.87.    
4.2.4. 5-[2-(Pyridin-4-ylamino)-thiazol-4-yl]-
isoxazole-3-carboxylic acid ethyl ester (3d) 
Yield 89%;  colorless solid; m.p. 165-167 
°C; IR (KBr, cm-1): 1727 (ester C=O), 3212 (N-H); 
1H NMR (300 MHz, DMSO-d6): δ = 1.32 (t, 3H, J = 
7.2 Hz, CH3 of ethyl), 4.39 (q, 2H, J = 6.9 Hz, CH2 of 
ethyl), 7.19 (s, 1H, Ar-H), 7.54-7.67 (m, 5H, Ar-H), 
8.12 (d, 1H, Ar-H), 13.06 (s, 1H, N-H) ppm; Anal. 
Calcd for C14H12N4O3S: C, 53.16: H, 3.82: N, 17.71. 
Found: C, 53.02: H, 3.71: N, 17.58.   
4.2.5. 5-(2-p-Tolylamino-thiazol-4-yl)-
isoxazole-3-carboxylic acid ethyl ester (3e) 
Yield 90%; colorless solid; m.p. 124-127 
°C; IR (KBr, cm-1): 1737 (ester C=O), 3334 (N-H); 
1H NMR (300 MHz, DMSO-d6): δ = 1.32 (t, 3H, J = 
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6.9 Hz, CH3 of ethyl), 2.26 (s, 3H, CH3), 4.39 (q, 2H, 
J = 7.2 Hz, CH2 of ethyl), 7.13-7.18 (m, 3H, Ar-H), 
7.55 (d, 2H, J = 8.4 Hz, Ar-H), 7.69 (s, 1H, Ar-H), 
10.38 (s, 1H, N-H) ppm; ESI-MS: m/z [M+1] 330; 
Anal. Calcd for C16H15N3O3S: C, 58.35: H, 4.59: N, 
12.76. Found: C, 58.22: H, 4.43: N, 12.61.   
4.2.6. 5-[2-(2,3-Dimethoxy-phenylamino)-
thiazol-4-yl]-isoxazole-3-carboxylic acid ethyl 
ester (3f) 
 Yield 86%; violet color solid; m.p. 137-
140 °C; IR (KBr, cm-1): 1731 (ester C=O),  3234 (N-
H); 1H NMR (300 MHz, DMSO-d6): δ = 1.32 (s, 3H, J 
= 6.9 Hz, CH3 of ethyl), 3.73 (s, 3H, OCH3), 3.78 (s, 
3H, OCH3), 4.35 (q, 2H, J = 7.2 Hz, CH2 of ethyl), 
6.94 (d, 1H, J = 8.7 Hz, Ar-H), 7.07 (s, 1H, Ar-H) 
7.18-7.21 (m, 1H, Ar-H), 7.34 (d, 1H, J = 2.1 Hz, Ar-
H), 7.67 (s, 1H, Ar-H), 10.31 (s, 1H, N-H) ppm; 
Anal. Calcd for C17H17N3O5S: C, 54.39: H, 4.56: N, 
11.19. Found:  C, 54.23: H, 4.41: N, 11.04.   
4.2.7. 5-(2-Benzoylamino-thiazol-4-yl)-
isoxazole-3-carboxylic acid ethyl ester (3g)  
Yield 93%; colorless solid; m.p; 196-198 
°C; IR (KBr, cm-1): 1683 (amide C=O), 1733 (ester 
C=O), 3230 (N-H); 1H NMR (300 MHz, DMSO-d6): δ 
= 1.32 (t, 3H, J = 7.2 Hz, CH3 of ethyl), 4.39 (q, 2H, J 
= 7.2 Hz, CH2 of ethyl), 7.19 (s, 1H, Ar-H), 7.54-
7.59 (t, 2H, J = 7.2Hz, Ar-H), 7.64 (d, 1H, J = 7.2Hz, 
Ar-H), 8.12 (d, 3H, J = 8.4Hz, Ar-H), 10.56 (s, 1H, N-
H, D2O exchangeable) ppm; 13C NMR (400 MHz, 
CDCl3): 14.58, 62.80, 101.68, 114.68, 128.02, 
129.53, 131.66, 133.87, 137.31, 157.30, 160.15, 
165.39, 166.59 ppm; Anal. Calcd for C16H13N3O4S: 
C, 55.97: H, 3.82: N, 12.24. Found: C, 55. 84: H, 
3.70: N, 12.11.  
4.2.8. [4-(3,4-Dihydro-2H-
benzo[b][1,4]dioxepin-7-yl)-thiazol-2-yl]-(4-
fluoro-phenyl)-amine (3h) 
Yield 92%; colorless solid; m.p. 192-194 
°C; IR (KBr, cm-1): 3192 (N-H); 1H NMR (300 MHz, 
DMSO-d6): δ = 2.10-2.13 (m, 2H, CH2 of 
trimethylenedioxy), 4.14-4.15 (m, 4H, 2xOCH2 of 
trimethylenedioxy), 6.76-7.51 (m, 7H, Ar-H), 9.49 
(s, 1H, Ar-H), 10.07 (s, 1H, N-H) ppm; Anal. Calcd 
for C18H15FN2O2S: C, 63.14: H, 4.42: N, 8.18. Found: 
C, 62.92: H, 4.30: N, 7.97. 
4.2.9. [4-(3,4-Dihydro-2H-
benzo[b][1,4]dioxepin-7-yl)-thiazol-2-yl]-(4-
chloro-phenyl)-amine (3i) 
 Yield 89%; colorless solid; m.p. 168-171 
°C; IR (KBr, cm-1): 3229 (N-H); 1H NMR (300 MHz, 
CDCl3): δ = 2.21-2.23 (m, 2H, J = 4.2 Hz, CH2 of 
trimethylenedioxy), 4.24-4.28 (m, 4H, 2xOCH2 of 
trimethylenedioxy), 6.56 (s, 1H, Ar-H), 7.03 (d, 1H, 
J = 6.0 Hz, Ar-H), 7.26-7.42 (m, 6H, Ar-H) ppm; 
Anal. Calcd for C18H15ClN2O2S: C, 60.25: H, 4.21: N, 
7.81. Found: C, 60.17: H, 4.03: N, 7.73.   
4.2.10. [4-(3,4-Dihydro-2H-
benzo[b][1,4]dioxepin-7-yl)-thiazol-2-yl]-(3-
trifluoromethyl-phenyl)-amine (3j) 
Yield 87%; colorless solid; m.p. 181-183 
°C; IR (KBr, cm-1): 3246 (N-H); 1H NMR (300 MHz, 
CDCl3): δ = 2.10-2.13 (m, 2H, CH2 of 
trimethylenedioxy), 4.16-4.18 (m, 4H, 2xOCH2 of 
trimethylenedioxy), 6.93-7.01 (m, 1H, Ar-H), 7.10 
(d, 1H, J = 8.4 Hz, Ar-H), 7.35 (s, 1H, Ar-H), 7.47-
7.51 (m, 2H, Ar-H), 7.72 (t, 1H, J = 6.9 Hz, Ar-H), 
8.30 (d, 1H, J = 6.6 Hz, Ar-H) ppm; Anal. Calcd for 
C19H15F3N2O2S: C, 58.16: H, 3.85: N, 7.14. Found: C, 
58.01: H, 3.68: N, 7.03.   
4.2.11. [4-(3,4-Dihydro-2H-
benzo[b][1,4]dioxepin-7-yl)-thiazol-2-yl]-
pyridin-2-yl-amine (3k) 
Yield 90%; colorless solid; m.p. 185-188 
°C; IR (KBr, cm-1): 3217 (N-H); 1H NMR (300 MHz, 
CDCl3): δ = 2.10-2.14 (m, 2H, CH2 of 
trimethylenedioxy), 4.13-4.18 (m, 4H, 2xOCH2 of 
trimethylenedioxy), 6.92 (d, 1H, J = 8.7 Hz, Ar-H), 
7.16-7.23 (m, 3H, Ar-H), 7.47 (t, 2H, J = 1.8Hz, Ar-
H), 7.70-7.75 (m, 2H, Ar-H), 10.26 (s, 1H, N-H) 
ppm; Anal. Calcd for C17H15N3O2S: C, 62.75: H, 
4.65: N, 12.91. Found: C, 62.60: H, 4.53: N, 12.78.     
4.2.12. [4-(3,4-Dihydro-2H-
benzo[b][1,4]dioxepin-7-yl)-thiazol-2-yl]-p-
tolyl-amine (3l)  
Yield 90%; colorless solid; m.p. 202-205 
°C; IR (KBr, cm-1): 3210 (N-H); 1H NMR (300 MHz, 
CDCl3): δ = 2.21-2.24 (m, 2H, CH2 of 
trimethylenedioxy), 2.38 (s, 3H, CH3), 4.26-4.29 
(m, 4H, 2xOCH2 of trimethylenedioxy), 6.45 (s, 1H, 
Ar-H), 7.05 (d, 1H, J = 6.3, Ar-H), 7.26-7.32 (d, 5H, J 
= 6.3 Hz, Ar-H), 7.38-7.41 (m, 1H, Ar-H), 11.56 (s, 
1H, N-H) ppm; Anal. Calcd for C19H18N2O2S: C, 
67.43: H, 5.36: N, 8.28. Found: C, 67.30: H, 5.21: N, 
8.13.     
4.2.13. 4-(3,4-Dihydro-2H-
benzo[b][1,4]dioxepin-7-yl)-thiazol-2-yl]-(2,3-
dimethoxy-phenyl)-amine (3m) 
Yield 92%; violet color solid; m.p. 201-
202 °C; solid; IR (KBr, cm-1): 3135 (N-H); 1H NMR 
(300 MHz, CDCl3): δ = 2.21-2.24 (m, 2H, J = 4.2 Hz, 
CH2 of trimethylenedioxy), 3.89 (s, 6H, 2,3-
Dimethoxy), 4.25-4.29 (m, 4H, 2xOCH2 of 
trimethylenedioxy), 6.45 (s, 1H, Ar-H), 6.89-6.95 
(m, 3H, Ar-H), 7.02 (d, 1H, J = 6.0 Hz, Ar-H), 7.32-
7.40 (m, 2H, Ar-H), 10.96 (s, 1H, N-H) ppm; Anal. 
Calcd for C20H20N2O4S: C, 62.48: H, 5.24: N, 7.29. 
Found: C, 62.30: H, 5.16: N, 7.13.   
4.2.14. N-[4-(3,4-Dihydro-2H-
benzo[b][1,4]dioxepin-7-yl)-thiazol-2-yl]-
benzamide (3n)  
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Yield 88%; colorless solid; m.p. 162-164 
°C; IR (KBr, cm-1): 1687 (amide C=O), 3210 (N-H); 
1H NMR (300 MHz, DMSO-d6): δ = 2.10-2.14 (m, 
2H, CH2 of trimethylenedioxy), 3.83-4.17 (m, 4H, 
2xOCH2 of trimethylenedioxy), 7.01-9.86 (m, 9H, 
Ar-H), 11.25 (s, 1H, N-H) ppm; Anal. Calcd for 
C19H16N2O3S: C, 64.76: H, 4.58: N, 7.95. Found C, 
64.62: H, 4.41: N, 7.84.  
4.2.15. (4-Fluoro-phenyl)-[4-(3-methyl-
benzo[b]thiophen-2-yl)-thiazol-2-yl]-amine 
(3o)  
Yield 91%; yellow color solid; m.p. 131-
133 °C; IR (KBr, cm-1): 3231 (N-H); 1H NMR (300 
MHz, DMSO-d6): δ = 2.61 (s, 3H, CH3), 7.18-7.23 
(m, 3H, Ar-H), 7.37-7.42 (m, 2H, Ar-H), 7.72-7.74 
(d, 2H, J = 6Hz, Ar-H), 7.81 (d, 1H, J = 7.8 Hz, Ar-H), 
7.93 (d, 1H, J = 7.8 Hz, Ar-H), 10.42 (s, 1H, N-H) 
ppm; Anal. Calcd for C18H13 FN2S2: C, 63.51: H, 
3.85: N, 8.23. Found: C, 63.36: H, 3.77: N, 8.10.   
4.2.16. (4-Chloro-phenyl)-[4-(3-methyl-
benzo[b]thiophen-2-yl)-thiazol-2-yl]-amine 
(3p)  
Yield 85%; colorless solid; m.p. 167-169 
°C; IR (KBr, cm-1): 3229 (N-H); 1H NMR (300 MHz, 
DMSO-d6): δ = 2.64 (s, 3H, CH3), 7.29 (s, 1H, Ar-H), 
7.36-7.45 (m, 2H, Ar-H), 7.49 (dd, 2H, J = 2.4, 9.0 
Hz, Ar-H), 7.57 (d, 1H, J = 8.7 Hz, Ar-H), 7.83 (d, 
1H, J = 7.2 Hz, Ar-H), 7.94 (d, 1H, J = 6.9 Hz, Ar-H), 
8.32 (d, 1H, J = 2.4 Hz, Ar-H), 10.76 (s, 1H, N-H) 
ppm; Anal. Calcd for C18H13ClN2S2: C, 60.58: H, 
3.67: N, 7.85. Found: C, 60.47: H, 3.54: N, 7.76.   
4.2.17. (3-Trifluoromethyl-phenyl)-[4-(3-
Methyl-benzo[b]thiophen-2-yl)-thiazol-2-yl]-
amine (3q) 
Yield 90%; yellow color solid; m.p. 216-
217 °C; IR (KBr, cm-1): 3219 (N-H); 1H NMR (300 
MHz, DMSO-d6): δ = 2.67 (s, 3H, CH3), 7.14 (t, 3H, J 
= 3.6 Hz, Ar-H), 7.34-7.44 (m, 2H, Ar-H), 7.58 (d, 
2H, J = 8.1 Hz, Ar-H), 7.81 (d, 1H, J = 7.8 Hz, Ar-H), 
7.93 (d, 1H, J = 7.8 Hz, Ar-H), 10.27 (s, 1H, N-H) 
ppm; Anal. Calcd for C19H13F3N2S2: C, 58.45: H, 
3.36: N, 7.17. Found: C, 58.39: H, 3.20: N, 7.08. 
4.2.18. [4-(3-Methyl-benzo[b]thiophen-2-yl)-
thiazol-2-yl]-pyridin-2-yl-amine (3r)  
Yield 94%; colorless solid; m.p. 155-158 
°C; IR (KBr, cm-1): 3229 (N-H); 1H NMR (300 MHz, 
DMSO-d6): δ = 2.68 (s, 3H, CH3), 7.12 (s, 1H, Ar-H), 
7.40-7.47 (m, 2H, Ar-H), 7.56 (t, 2H, J = 5.4 Hz, Ar-
H), 7.65-7.69 (m, 1H, Ar-H), 7.76 (dd, 1H, J = 2.4, 
5.4 Hz, Ar-H), 7.83 (dd, 1H, J = 1.8, 4.8 Hz, Ar-H), 
8.25 (d, 2H, J = 5.4 Hz, Ar-H), 12.66 (s, 1H, N-H) 
ppm; Anal. Calcd for C17H13N3S2: C, 63.13: H, 4.05: 
N, 12.66. Found: C, 62.98: H, 3.86: N, 12.45.  
4.2.19. [4-(3-Methyl-benzo[b]thiophen-2-yl)-
thiazol-2-yl]-p-tolyl-amine (3s) 
Yield 90%; colorless solid; m.p. 138-140 
°C; IR (KBr, cm-1): 3238 (N-H); 1H NMR (300 MHz, 
DMSO-d6): δ = 2.27 (s, 3H, CH3), 2.61 (s, 3H, CH3 of 
benzothiophene), 7.14 (t, 3H, J = 3.9 Hz, Ar-H), 
7.34-7.44 (m, 2H, Ar-H), 7.58 (d, 2H, J = 8.4 Hz, Ar-
H), 7.81 (d, 1H, J = 7.2 Hz, Ar-H), 7.93 (d, 1H, J = 6.9 
Hz, Ar-H), 10.28 (s, 1H, N-H) ppm; Anal. Calcd for 
C19H16N2S2: C, 67.82: H, 4.79: N, 8.33. Found: C, 
67.69: H, 4.68: N, 8.20.  
4.2.20. (2,3-Dimethoxy-phenyl)-[4-(3-methyl-
benzo[b]thiophen-2-yl)-thiazol-2-yl]-amine 
(3t) 
Yield 86%; violet color solid; m.p. 185-
186 °C; IR (KBr, cm-1): 3323 (N-H); 1H NMR (300 
MHz, DMSO-d6): δ = 2.62 (s, 3H, CH3), 3.73 (s, 3H, 
OCH3), 3.84 (s, 3H, OCH3), 6.93 (d, 1H, J = 8.7 Hz, 
Ar-H), 7.05 (dd, 1H, J = 2.4, 8.4 Hz, Ar-H), 7.14 (s, 
1H, Ar-H), 7.34-7.44 (m, 2H, Ar-H), 7.63 (d, 1H, J = 
2.4 Hz, Ar-H), 7.81 (d, 1H, J = 7.5 Hz, Ar-H), 7.91 (d, 
1H, J = 7.5 Hz, Ar-H), 10.22 (s, 1H, N-H) ppm; Anal. 
Calcd for C20H18N2O2S2: C, 62.80: H, 4.74: N, 7.32. 
Found: C, 62.63: H, 4.61: N, 7.23.  
4.2.21. N-[4-(3-Methyl-benzo[b]thiophen-2-
yl)-thiazol-2-yl]-benzamide (3u)  
Yield 86%; colorless solid; m.p. 220-222 
°C; IR (KBr, cm-1): 3214 (N-H), 1680 (amide C=O); 
1H NMR (300 MHz, DMSO-d6): δ = 2.61 (s, 3H, 
CH3), 7.18-7.23 (m, 3H, Ar-H), 7.37-7.42 (m, 2H, 
Ar-H), 7.72-7.77 (m, 2H, Ar-H), 7.82 (d, 1H, J = 7.5 
Hz, Ar-H), 7.93 (d, 1H, J = 7.8 Hz Ar-H), 10.42 (s, 
1H, N-H) ppm; Anal. Calcd for C19H14N2OS2: C, 
65.12: H, 4.03: N, 7.99. Found: C, 64.97: H, 3.89: N, 
7.84.   
5. CONCLUSION 
In summary, a series of novel compounds 
containing isoxazole, benzodioxepin and 
benzothiophene core with thiazole moiety have 
been synthesized and evaluated for their cytotoxic 
activity against DAL and EAC cell lines. Results 
showed that the most of these compounds 
possessed potent cytotoxic activity against DAL 
and EAC cell lines with IC50 values in low micro 
molar range. Among these, the compound N-[4-(3-
methyl-benzo[b]thiophen-2-yl)-thiazol-2-yl]-
benzamide (3u) is found to be the most cytotoxic 
compound against DAL cell line with IC50 value of 
15.76 µg/mL and the compound 5-[2-(pyridin-4-
ylamino)-thiazol-4-yl]-isoxazole-3-carboxylic acid 
ethyl ester (3d) is found to be the most cytotoxic 
compound against EAC cell line with IC50 value of 
28.73 µg/mL.    
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